---
title: "Morgan Stanley: Eli Lilly's oral weight loss drug clinical trial data is impressive, maintaining target price of $1028"
description: "Morgan Stanley released a report stating that Eli Lilly's oral GLP-1 receptor agonist Orfor performed excellently in Phase III clinical trials for obesity treatment, demonstrating good weight loss eff"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257848381.md"
published_at: "2025-09-18T06:53:03.000Z"
---

# Morgan Stanley: Eli Lilly's oral weight loss drug clinical trial data is impressive, maintaining target price of $1028

> Morgan Stanley released a report stating that Eli Lilly's oral GLP-1 receptor agonist Orfor performed excellently in Phase III clinical trials for obesity treatment, demonstrating good weight loss effects and improvements in cardiovascular metabolic indicators. The firm maintains an "Overweight" rating on Eli Lilly, with a 12-month target price of $1,028. Orfor has shown clinical value in terms of weight loss effects, metabolic indicators, and safety, particularly demonstrating a higher normalization rate of blood sugar in prediabetic patients

According to Zhitong Finance APP, Morgan Stanley published a research report stating that Eli Lilly (LLY.US) recently announced the Phase III clinical trial (ATTAIN-1) data for its oral GLP-1 receptor agonist Orforglipron (Orfor) for the treatment of obesity. The firm pointed out that Orfor has demonstrated excellent results in weight loss, improvement of cardiovascular metabolic indicators, and safety. The newly released data did not change its positive outlook on Orfor's prospects, maintaining an "Overweight" rating for Eli Lilly with a 12-month target price of $1,028.

Morgan Stanley stated that the complete data from the ATTAIN-1 clinical trial showcased Orfor's clinical value from multiple dimensions, including weight loss effects, improvement of metabolic indicators, changes in body composition, and safety.

In terms of weight loss effects, all three dosage groups experienced a plateau in weight loss between weeks 48 and 72. Although the duration of the ATTAIN-1 trial was longer, the weight loss effect at 72 weeks was comparable to that at 36 weeks in the Phase II trial. Researchers analyzed that this may be related to trial design and population differences, such as a male proportion of 36%. Notably, in Novo Nordisk's (NVO.US) OASIS 4 trial of oral semaglutide 25mg, weight loss also plateaued between weeks 48 and 64, with a male proportion of about 24%.

Regarding the improvement of metabolic indicators, Orfor significantly improved several cardiovascular metabolic risk factors, including waist circumference, systolic blood pressure, non-high-density lipoprotein cholesterol, and triglycerides. It also showed improvements in diastolic blood pressure, other lipid components, high-sensitivity C-reactive protein, glycated hemoglobin, fasting blood glucose, and fasting insulin, with a higher normalization rate of blood glucose in prediabetic patients.

In terms of changes in body composition, combined analysis of the Orfor treatment group data showed that 73.1% of weight loss was due to a reduction in fat mass, while 26.9% came from a decrease in lean body mass, with fat reduction being dominant.

Regarding safety and tolerability, the adverse reactions of Orfor were consistent with other GLP-1 drugs, primarily mild to moderate gastrointestinal events, mostly occurring during the dose escalation period. Liver safety assessments showed comprehensive monitoring of liver safety during the trial, with no clear drug-related liver injury found.

Morgan Stanley believes that Orfor is particularly suitable for the obesity population with a lower BMI (<35), as well as patients who prefer oral therapy or cannot access injectable medications, including patient groups in low- to middle-income countries, with market potential expected to be further released.

Overall, Morgan Stanley stated that the successful launch of Orfor, the expansion of its other weight loss drug tirzepatide in the obesity field, and the accelerated supply of automatic injectors may bring upside risks, while the failure of Orfor's development and strong competitive data may pose downside risks

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元 | 礼来第四季度营收为 192.9 亿美元，同比增长 43%。预计全年营收为 800 亿至 830 亿美元，市场预期为 777.1 亿美元。 | [Link](https://longbridge.com/en/news/274805260.md) |
| 礼来公司（LLY）建立了价值 15 亿美元的减肥药库存 | 礼来（LLY）已准备好 15 亿美元的库存，以迎接其新减肥药 Orforglipron 预计在四月获得 FDA 批准。该公司计划在今夏推出该药，并进行大规模的营销活动，以与诺和诺德的 Wegovy 竞争。分析师对礼来的股票给予了一致的强烈买 | [Link](https://longbridge.com/en/news/276070062.md) |
| 美股盘中速递：脑再生科技跌 12.82%，市场情绪波动显著，资金流向引发关注 | 脑再生科技跌 12.82%；强生跌 1.51%，成交额达到 14.03 亿美元；礼来跌 0.83%，成交额达到 13.12 亿美元；辉瑞跌 1.47%，成交额达到 3.95 亿美元；阿斯利康跌 0.64%，市值达到 3181 亿美元。 | [Link](https://longbridge.com/en/news/276469327.md) |
| 美股盘中速递：NovaBay 制药涨 26.73%，剥离非核心业务引发市场热情与信心提升 | NovaBay 制药涨 26.73%；强生跌 2.40%，成交额达到 7.66 亿美元；礼来跌 1.65%，成交额达到 7.35 亿美元；默克涨 0.01%，成交额达到 2.06 亿美元；阿斯利康跌 0.15%，市值达到 3197 亿美元。 | [Link](https://longbridge.com/en/news/276459970.md) |
| 美股盘中速递：Nasus Pharma 涨 17.60%，投资者会议提振信心，生命科学行业强劲表现助力股价上扬 | Nasus Pharma 涨 17.60%；礼来跌 0.94%，成交额达到 11.54 亿美元；强生跌 1.93%，成交额达到 11.54 亿美元；默克跌 0.30%，成交额达到 3.13 亿美元；阿斯利康跌 0.35%，市值达到 3191 | [Link](https://longbridge.com/en/news/276465601.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.